Back to top
more

Corvus Pharmaceuticals (CRVS)

(Delayed Data from NSDQ)

$14.72 USD

14.72
508,073

-0.01 (-0.07%)

Updated Aug 27, 2026 04:00 PM ET

After-Market: $14.74 +0.02 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why

by Zacks Equity Research

Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.

Zacks Equity Research

Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

The Zacks Analyst Blog Highlights: Condor Hospitality Trust, Corvus Pharmaceuticals, Covenant Logistics and Herc Holdings

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Condor Hospitality Trust, Corvus Pharmaceuticals, Covenant Logistics and Herc Holdings

Sejuti Banerjea headshot

4 Buy-Ranked Stocks that Soared Over 20% in the Past Week

by Sejuti Banerjea

The market remains on its toes as investors digest the ton of information hitting us about now.

Zacks Equity Research

Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study

by Zacks Equity Research

Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.

Zacks Equity Research

Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study

by Zacks Equity Research

Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the same.

Zacks Equity Research

Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan

by Zacks Equity Research

Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.

Zacks Equity Research

Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Corvus Pharmaceuticals (CRVS) stock based on the movements in the options market lately.

Zacks Equity Research

BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

by Zacks Equity Research

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

Zacks Equity Research

RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

by Zacks Equity Research

RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.